BRIEF published on 09/05/2024 at 09:05, 1 year 11 months ago Biotest AG ouvre son 13e centre de collecte de plasma en Allemagne Allemagne Biotest AG Collecte De Plasma Traitements Médicaux Défense Des Droits Des Patients
PRESS RELEASE published on 09/05/2024 at 09:00, 1 year 11 months ago Biotest AG opens 13th plasma collection center in Germany Biotest AG opens 13th plasma collection center in Germany to ensure long-term plasma supply. State-of-the-art center in Karlsruhe operated by Plasma Service Europe GmbH, a subsidiary of Biotest AG Donations Germany Biotest AG Plasma Collection Center Plasma Service Europe GmbH
BRIEF published on 08/28/2024 at 09:05, 2 years ago Dr. Jörg Schüttrumpf Resigns from Biotest AG Management Board Management Board Biotest AG Product Development Jörg Schüttrumpf Grifols Group
BRIEF published on 08/28/2024 at 09:05, 2 years ago Le Dr Jörg Schüttrumpf démissionne du conseil d'administration de Biotest AG Conseil D'administration Biotest AG Développement De Produits Jörg Schüttrumpf Groupe Grifols
PRESS RELEASE published on 08/28/2024 at 09:00, 2 years ago Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG Dr. Jörg Schüttrumpf resigns as Chief Scientific Officer of Biotest AG to focus on role as Chief Scientific Innovation Officer of Grifols Group, effective August 31, 2024 Resignation Management Board Biotest AG Grifols Group Dr. Jörg Schüttrumpf
BRIEF published on 08/06/2024 at 09:05, 2 years ago Biotest Sees 35% Sales Spike in First Half of 2024 Financial Results Revenue Growth FDA Approval Biotest Yimmugo®
BRIEF published on 08/06/2024 at 09:05, 2 years ago Biotest voit ses ventes augmenter de 35 % au premier semestre 2024 Résultats Financiers Hausse Des Revenus Approbation De La FDA Biotest Yimmugo®
PRESS RELEASE published on 08/06/2024 at 09:00, 2 years ago Biotest increases sales in the first half of 2024 by 35% to Euro 372 million Biotest AG reports 35% sales increase to Euro 372 million in H1 2024. EBIT reaches Euro 78.4 million. FDA approves Yimmugo® and BNL facility. Positive revenue and earnings growth Revenue Growth FDA Approval Sales Increase Biotest AG H1 2024
BRIEF published on 07/30/2024 at 08:05, 2 years 1 month ago Biotest Reports 35% Increase in Sales for First Half of 2024 Financial Results Revenue Increase FDA Approval Sales Growth Biotest AG
BRIEF published on 07/30/2024 at 08:05, 2 years 1 month ago Biotest annonce une augmentation de 35 % de ses ventes pour le premier semestre 2024 Résultats Financiers Approbation De La FDA La Croissance Des Ventes Augmentation Des Revenus Biotest SA
Published on 09/02/2026 at 15:00, 33 minutes ago Vox Royalty Enters into Binding Agreement to Acquire the White Dam Gold Royalty in Australia
Published on 09/02/2026 at 14:30, 1 hour 3 minutes ago Solitario Completes Phase-One Drilling at Golden Crest - Reports Initial Drill Results for Ponderosa
Published on 09/02/2026 at 14:00, 1 hour 33 minutes ago Orogen Royalties Acquires Two Gold Projects in Southwest Utah
Published on 09/02/2026 at 14:00, 1 hour 33 minutes ago Datametrex Plans to Focus on AI, Data Centre, and Patent Licensing
Published on 09/02/2026 at 13:00, 2 hours 33 minutes ago Snipp-Powered Loyalty Programs Earn Two Gold Awards at Loyalty360 Awards
Published on 09/02/2026 at 14:30, 1 hour 3 minutes ago Partners Group invests in next phase of growth for atNorth
Published on 09/02/2026 at 13:00, 2 hours 33 minutes ago Nebius to participate in upcoming investor conferences
Published on 09/02/2026 at 12:30, 3 hours 3 minutes ago Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
Published on 09/02/2026 at 11:09, 4 hours 23 minutes ago Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Published on 09/02/2026 at 07:43, 7 hours 49 minutes ago Accor launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2032 for a nominal amount of €380 million and a concurrent partial repurchase offer with respect to its outstanding OCEANEs due 2027 by
Published on 09/02/2026 at 07:43, 7 hours 49 minutes ago Accor lance une émission d’obligations à option de conversion en actions nouvelles et/ou d’échange en actions existantes (OCEANEs) à échéance 2032 pour un montant nominal de 380 millions d’euros et une offre concomitante de rachat partiel de s
Published on 09/01/2026 at 19:00, 20 hours 33 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 09/01/2026 at 19:00, 20 hours 33 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
